Cargando…
Aflibercept in wet AMD beyond the first year of treatment: recommendations by an expert roundtable panel
This supplement has been sponsored by Bayer HealthCare. Please see acknowledgements for full disclaimer. Prescribing Information can be found in the appendices. L.GB.COM.05.2015.11280. Date of preparation: June 2015 This paper provides expert recommendations on administration of aflibercept in wet a...
Autores principales: | McKibbin, M, Devonport, H, Gale, R, Gavin, M, Lotery, A, Mahmood, S, Patel, P J, Ross, A, Sivaprasad, S, Talks, J, Walters, G |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4506328/ https://www.ncbi.nlm.nih.gov/pubmed/26156564 http://dx.doi.org/10.1038/eye.2015.77 |
Ejemplares similares
-
Aflibercept treatment for neovascular AMD beyond the first year: consensus recommendations by a UK expert roundtable panel, 2017 update
por: Patel, Praveen J, et al.
Publicado: (2017) -
Appropriateness of quality standards for meaningful intercentre comparisons of aflibercept service provision for neovascular age-related macular degeneration
por: Talks, J S, et al.
Publicado: (2017) -
Recommendations by a UK expert panel on an aflibercept treat-and-extend pathway for the treatment of neovascular age-related macular degeneration
por: Ross, Adam H., et al.
Publicado: (2020) -
Aflibercept in wet AMD: specific role and optimal use
por: Semeraro, F, et al.
Publicado: (2013) -
Associations with visual acuity outcomes after 12 months of treatment in 9401 eyes with neovascular AMD
por: Relton, SD, et al.
Publicado: (2022)